Dantrolene A Treatment for Alzheimers Disease?

摘要

Alzheimer's disease (AD) is a fatal progressive disease and the most common form of dementia without effective treatments. Previous studies support that the disruption of endoplasmic reticulum (ER) Ca²⁺ via overactivation of Ryanodine receptors (RYRs) plays an important role in the pathogenesis of AD. Normalization of intracellular Ca²⁺ homeostasis could be an effective strategy for AD therapies. Dantrolene, an antagonist of RYRs and an FDA approved drug for clinical treatment of malignant hyperthermia and muscle spasms, exhibits neuroprotective effects in multiple models of neurodegenerative disorders. Recent preclinical studies consistently support the therapeutic effects of dantrolene in various types of AD animal models and were summarized in the current review.